In contrast to our data, in another transplantable BRAFV600E‐murine melanoma model, BRAFi treatment led to a reduction of CCL2 mRNA expression and a reduction in secretion of CCL2 from tumor cells.11 In line, Steinberg et al. observed less CCL2 mRNA under BRAFi, which was restored in resistant tumors favoring MDSC recruitment. The gene discussed is CCL2; the disease is melanoma.